These data suggest that chronic ACE inhibition provides beneficial effects, such as lowering lipid levels secondary to reducing proteinuria during the early progression of renal injury associated with obesity. The gene discussed is ACE; the disease is obesity due to melanocortin 4 receptor deficiency.